AbbVie’s Venclexta granted full US approval in AML
FDA approved therapy for newly-diagnosed acute myeloid leukaemia patients
Read More
Tag: Venclexta
Venclexta/Venclyxto combo extends myeloid leukaemia survival
Roche also reported that safety for Venclexta/Venclyxto with azacitidine appeared consistent with the known safety profile of these medicines.
Read More
Venclexta safety warnings in multiple myeloma patients
US regulators have posted a safety statement warning of an increased risk of death for patients receiving AbbVie’s venetoclax with bortezomib and dexamethasone for melanoma patients.
Read More
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Read More
Roche’s Venclexta filed in the US for acute myeloid leukemia
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
Read More
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
